FIELD: organic chemistry.
SUBSTANCE: group of inventions includes dantrolene prodrugs of formula I or their pharmaceutically acceptable salts, a pharmaceutical composition containing them, and a compound of formula III. In the formula I, R is -P(O)(OH)2 or -P(O)(OR1)(OR2); R1 represents either H or -C1-6alkyl; and R2 represents -C1-6alkyl.
EFFECT: obtaining dantrolene prodrugs with high solubility in water.
11 cl, 17 dwg, 4 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF DANTROLENE AND DANTROLENE PRODRUGS FOR TREATMENT OF RADIATION EXPOSURE | 2019 |
|
RU2812220C2 |
| CARBIDOPA AND L-DOPA PRODRUGS AND USE THEREOF FOR TREATING PARKINSON'S DISEASE | 2015 |
|
RU2743347C2 |
| METHODS OF USING DANTROLENE FOR TREATING NERVE AGENT EXPOSURE | 2018 |
|
RU2817851C2 |
| COMPOSITIONS OF DANTROLENE AND METHODS OF THEIR USE | 2019 |
|
RU2809143C2 |
| SUBSTITUTED TRIA-AZOLES AND METHODS RELATING THERETO | 2016 |
|
RU2718049C2 |
| CYSTATHIONINE-G-LYASE (CSE) INHIBITORS | 2013 |
|
RU2640418C2 |
| COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | 2010 |
|
RU2600736C2 |
| CONJUGATES OF HYDROCODONE WITH BENZOIC ACID, DERIVATIVES OF BENZOIC ACID AND HETERO-ACRYL-CARBON ACID, PRODRUGS, METHODS FOR THEIR OBTAINING AND APPLICATION | 2010 |
|
RU2505541C2 |
| METHYLHYDROFUMARATE PRODRUGS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR USING | 2009 |
|
RU2554347C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL AND PSYCHOACTIVE SUBSTANCE-RELATED DISORDERS | 2016 |
|
RU2715384C2 |
